NSAID-INDUCED ESOPHAGOPATHY: JUST GERD OR ANOTHER DISEASE ENTITY?
- Authors: Pakhomova I.G1, Khoroshinina L.P1,2
-
Affiliations:
- NWSMU n.a. I.I. Mechnikov
- NWFMSC n.a. V.A. Almazov
- Issue: No 15 (2016)
- Pages: 39-43
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289218
- ID: 289218
Cite item
Open Access
Access granted
Abstract
To date, there is ample evidence that the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with the risk of side effects from the esophagus, which not only reduce the quality of life of patients, but may be a direct threat to their lives, and practical application of selective NSAIDs did not completely solve this problem. Due to accompanying with symptoms of gastroesophageal reflux disease (GERD), and the widespread use of NSAIDs in clinical practice, the question about the allocation of NSAID-induced lesions of the esophagus in separate disease entity is aroused. Proton pump inhibitors are now the drugs of choice for the treatment of manifestations of the syndrome of NSAID-associated lesions of the esophagus, among which esomeprazole deserves special attention in the light of this problem.
Full Text
About the authors
I. G Pakhomova
NWSMU n.a. I.I. Mechnikov
Email: pakhomova-inna@yandex.ru
PhD, Assistant Professor at the Department of Propaedeutics of Internal Diseases
L. P Khoroshinina
NWSMU n.a. I.I. Mechnikov; NWFMSC n.a. V.A. Almazov
References
- Bigard M., Pelletier A. Esophageal complications of non steroidal antiinflammatory drugs. Gastroenterol. Clin. Biol. 2004; 3: 58-61.
- Каратеев А.Е., Успенский Ю.П., Пахомова И.Г., Насонов Е.Л. Прием НПВП и патология пищевода: связь с основными симптомами гастроэзофагеальной рефлюксной болезни, частота развития и факторы риска эрозивного эзофагита. Эксперим. и клин. гастроэнтерол. 2008; 3: 6-11.
- Ruszniewski P., Soufflet C., Barthelemy P., Colin R. NSAIDs intakes is a risk factor for gastroesophageal reflux. Gut. 2006; 55(V): A267.
- Avidan B. Sonnenberg A., Schnell T. Risk factors of oesophagitis in arthritic patients. Eur. J. Gastroenterol. Hepatol. 2001; 13: 1095-1099.
- Пахомова И.Г., Успенский Ю.П., Едемская М.А., Егошина В.А, Каратеев А.Е. Поражения пищевода у больных остеоартрозом, принимающих нестероидные противовоспалительные препараты. Практическая медицина. 2012; 3: 86-90.
- Bassotti G., Bucaneve G., Furno P. Double-blind, placebo-controlled study on effect of diclofenac sodium and indomethacin on postprandial gastric motility in men. Digest. Dis. Sci. 1998; 43: 1172-176.
- Kenneth D. Gastroesophageal reflux and asthma in the elderly patient. J. Allerg. Clin. Immunol. 1997; 17(4): 645-58.
- Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации / Под ред. А.Е. Каратеева. М., 2009. 167 с.
- Mantry P., Shah A., Sundaram U. Celecoxib associated esophagitis: review of gastrointestinal side effects from COX-2 inhibitors. J. Clin. Gastroenterol. 2003; 37: 61-3.
- Инструкция по медицинскому применению препарата. Регистрационный номер: № 013775/01.
- Hawkey C., Jones R., Yeomans N., Scheiman J.M., Talley N.J., Goldstein J.L., Ahlbom H., Naesdal J. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal antiinflammatory drugs. Aliment. Pharmacol. Ther. 2007; 25(7): 813-21.
- Andersson Т., Rohss K., Hassan-Alin M. Pharmacokinetics (PK) and dose-response relationship of esomeprazole (E). Gastroenterology. 2000; 118: A1210.
- Hawkey C.J., Talley N.J., Scheiman J.M. et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthr. Res. Ther. 2007; 9: R17.
- Talley N., Venables Т., Green J. Esomeprazole 40 mg and 20 mg is efficacious in the longterm management of patients with endoscopy-negative GERD: a placebo-controlled trial of on-demand therapy for 6 months. Gastroenterol. 2000; 118: A658.
- Johnson D., Benjamin S., Vakil N. et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive eosopha-gitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am. J. Gastroenterol. 2001; 96: 27-34.
- Vakil N., Shaker R., Johnson D., et al. The new proton pump inhibitor esomeprazole is effective as a maintanence therapy in GERD patients with healed erosive eosophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment. Pharmacol. Ther. 2001; 15: 927-35.
- Lind Т., Rydberg L., Kyleback A., Jonsson A., Andersson T., Hasselgren G., Holmberg J., Röhss K. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2000; 14: 861-67.
Supplementary files
